

Volume 22: Issue 2; 2018

IN THIS ISSUE

PUBLICATIONS ON THE COCHRANE LIBRARY (THE CLIB). FROM 10 OF APRIL TO 7 OF NOVEMBER 2018 (COCHRANE DATABASE OF SYSTEMATIC REVIEWS)

NEW REVIEWS

UPDATED REVIEWS

NEW OR MAJOR UPDATED PROTOCOLS

FEEDBACK ON PUBLISHED PROTOCOLS OR REVIEWS

NEW REGISTERED TITLES

PAST EVENTS

CHBG PRESENTATION AND EXHIBITION STAND DURING THE INTERNATIONAL LIVER CONGRESS (EASL). 12 TO 14 APRIL 2018, PARIS, FRANCE

COCHRANE COLLOQUIUM. 16 TO 18 SEPTEMBER 2018, EDINBURGH, UK

FUTURE EVENTS

CHBG EXHIBITION STAND DURING THE 70TH ANNUAL LIVER MEETING (AMERICAN ASSOCIATION FOR THE STUDY OF LIVER DISEASES). 9 TO 13 NOVEMBER 2018, SAN FRANCISCO, CA, USA

VISITORS

THE COCHRANE SCIENTIFIC COMMITTEE

STAY UPDATED

The numbering is a continuation from The CHBG Newsletter 2018; Vol. 22: Issue 1 and covers reviews published between 10 of April and 7 of November 2018.

PUBLICATIONS ON THE COCHRANE LIBRARY (THE CLIB). FROM 10 OF APRIL TO 7 OF NOVEMBER 2018 (COCHRANE DATABASE OF SYSTEMATIC REVIEWS)

NEW REVIEWS

214. Glucocorticosteroids for infants with biliary atresia following Kasai portoenterostomy. Tyriskis A, Parsons C, Davenport M.

215. L-ornithine L-aspartate for prevention and treatment of hepatic encephalopathy in people with cirrhosis. Goh ET, Stokes CS, Sidhu SS, Vilstrup H, Gluud LL, Morgan MY.

216. Surgical portosystemic shunts versus devascularisation procedures for prevention of variceal rebleeding in people with hepatosplenic schistosomiasis. Ede CJ, Nikolova D, Brand M.

217. Transabdominal ultrasound and endoscopic ultrasound for diagnosis of gallbladder polyps. Wennmacker SZ, Lamberts MP, Di Martino M, Drenth JPH, Gurusamy KS, van Laarhoven CJHM.

218. Carvedilol versus traditional, non-selective beta-blockers for adults with cirrhosis and gastroesophageal varices. Zacharias AP, Jeyaraj R, Hobolth L, Bendtsen F, Gluud LL, Morgan MY.

219. Surgical portosystemic shunts versus transjugular intrahepatic portosystemic shunt for variceal haemorrhage in people with cirrhosis. Brand M, Prodehl L, Ede CJ.

UPDATED REVIEWS

None

NEW OR MAJOR UPDATED PROTOCOLS

360. Bile acids for cholelithiasis. Gana JC, Gattini D, Villarroel del Pino LA, Larraín Castellón S, Yap J.

361. Aluminium adjuvants used in vaccines. Djuricic S, Jakobsen JC, Petersen SB, Kenfelt M, Klingenberg SL, Gluud C.
362. Entecavir versus other oral antiviral drugs for chronic hepatitis B. Ismail MH, Ricafort-Campos JD, Wiysonge CS, Gish R.
363. Acupuncture for chronic hepatitis B. Kong DZ, Liang N, Yang GL, Zhang Z, Liu Y, Yang Y, Liu YX, Wang QG, Zhang F, Zhang HY, Nikolova D, Jakobsen JC, Gluud C, Liu JP.
364. Radix Sophorae flavescentis for chronic hepatitis B. Liang N, Kong DZ, Nikolova D, Gluud C, Jakobsen JC, Liu JP.
365. Radix Sophorae flavescentis versus antiviral drugs for chronic hepatitis B. Liang N, Kong DZ, Nikolova D, Jakobsen JC, Gluud C, Liu JP.
366. Xiao Chai Hu Tang, a Chinese herbal medicine formula, for chronic hepatitis B. Kong DZ, Liang N, Liu JP, Nikolova D, Jakobsen JC, Gluud C.
367. Treatment for hepatorenal syndrome in people with decompensated liver cirrhosis: a network meta-analysis. Best LMJ, Freeman S, Sutton AJ, Hawkins N, Tsochatzis E, Gurusamy KS.
368. Treatment for ascites in people with decompensated liver cirrhosis: a network meta-analysis. Gurusamy KS, Tsochatzis E.
369. Secondary prevention of bleeding in people with previous oesophageal variceal bleeding due to decompensated liver cirrhosis: a network meta-analysis. Gurusamy KS, Tsochatzis E.
370. Primary prevention of bleeding in people with oesophageal varices due to liver cirrhosis: a network meta-analysis. Gurusamy KS, Tsochatzis E.
371. Antibiotic treatment for spontaneous bacterial peritonitis in people with decompensated liver cirrhosis: a network meta-analysis. Gurusamy KS, Wilson P, Tsochatzis E.
372. Antibiotic prophylaxis to prevent spontaneous bacterial peritonitis in people with liver cirrhosis: a network meta-analysis. Gurusamy KS, Wilson P, Tsochatzis E.
373. Treatment for bleeding oesophageal varices in people with decompensated liver cirrhosis: a network meta-analysis. Roberts D, Tsochatzis E, Gurusamy KS.
374. Nutritional supplementation for non-alcohol-related fatty liver disease: a network meta-analysis. Gurusamy KS, Tsochatzis E, Madden AM.
375. Lifestyle modifications for non-alcohol related fatty liver disease: a network meta-analysis. Gurusamy KS, Tsochatzis E, Madden AM.
376. Perioperative antioxidants for adults undergoing elective non-cardiac surgery. Stevens JL, McKenna H, Gurusamy KS, Van Schoor J, Grocott MPW, Jell G, Martin D.
377. Antibiotic prophylaxis versus placebo or no intervention for people with cirrhosis and variceal bleeding. Sanchez-Jimenez B, Chavez-Tapia NC, Jakobsen JC, Nikolova D, Gluud C.

FEEDBACK ON PUBLISHED PROTOCOLS OR REVIEWS

Further feedback has been received on the review protocol 'Aluminium adjuvants used in vaccines versus placebo or no intervention' by Djuricic S, Jakobsen JC, Petersen SB, et al, and the review 'Direct-acting antivirals for chronic hepatitis C' by Jakobsen JC, Nielsen EE, Feinberg J, et al. The feedback and replies are published in The Cochrane Library. So far, we cannot provide a date when the review on aluminium will be published.

NEW REGISTERED TITLES

532. Endoscopic and percutaneous transhepatic biliary drainage in the palliative management of malignant biliary obstruction in patients unsuitable for potentially curative resection of hepatobiliary cancers. Ney A, Goodchild. Gurusamy KS, Pereira SP.
533. Non-selective shunts versus selective shunts for preventing and treating variceal rebleeding in people with portal hypertension. Ede CJ, Ede R, Brand M.
544. Antibiotic prophylaxis for people with cirrhosis and variceal bleeding. Sanchez-Jimenez B, Chavez-Tapia NC, Jakobsen JC, Nikolova D, Gluud C.
545. Stents for biliary tract strictures in people with non-cancerous bile duct lesions. Giusti MFranchini, Fonseca AV, Vasconcelos V, Gomes Jr CAAR, Waisberg J.
546. Induction immunosuppression in adults undergoing liver transplantation: a network meta-analysis. Gurusamy KS, Tsochatzis E.
547. Toll-like receptor 7 (TLR7) agonist (GS-9620) versus pegylated-interferon- α for chronic hepatitis B. Chen F, Chen X, Peng D, Chen Z, Zheng M, Hu Y.
548. Antibiotic prophylaxis versus placebo or no intervention for people with cirrhosis and variceal bleeding. Sanchez-Jimenez B, Chavez-Tapia NC, Jakobsen JC, Nikolova D, Gluud C.

549. Antibiotics for people with cholangitis or cholecystitis or both. Markotic F, Grgic S, Fox A.

PAST EVENTS

CHBG PRESENTATION AND EXHIBITION STAND DURING THE INTERNATIONAL LIVER CONGRESS (EASL). 12 TO 14 APRIL 2018, PARIS, FRANCE

Christian Gluud presented the Direct-acting antivirals for chronic hepatitis C review (available from the Cochrane Database of Systematic Reviews 2017, Issue 9. Art. No.: CD012143. DOI: 10.1002/14651858.CD012143.pub3) during the “Critical reflection on landmark papers 2017” session on April 13 from 17:30 to 18:00.

The CHBG stand was also well attended.

COCHRANE COLLOQUIUM. 16 TO 18 SEPTEMBER 2018, EDINBURGH, UK

The theme of the colloquium was “Cochrane for all: making the Colloquium a 'Patients Included' event”. The CHBG Editorial Team office staff (3 people) attended the colloquium.

The CHBG was introduced to the newly appointed Senior editor, Cindy Farquhar, of the Long-term Conditions and Aging Network 1 (see p.4), to which our CHBG belongs to. Cindy Farquhar is a Postgraduate Professor of Obstetrics and Gynaecology in the Department of Obstetrics and Gynaecology at the University of Auckland, and Co-ordinating Editor of Cochrane Gynaecology and Fertility group, among others. Liz Bickerdike, London, is the appointed Associate Editor of our Network 1. Both Liz and Cindy receive CHBG reviews with requests for approval before publication.

You may read about the latest Cochrane organizational structure at

<https://www.cochrane.org/about-us/our-global-community>

FUTURE EVENTS

CHBG EXHIBITION STAND DURING THE 70TH ANNUAL LIVER MEETING (AMERICAN ASSOCIATION FOR THE STUDY OF LIVER DISEASES). 9 TO 13 NOVEMBER 2018, SAN FRANCISCO, CA, USA

The CHBG exhibition stand is number 112. You are most welcome to pay us a visit. Neither this year, we will run a CHBG affiliated meeting event because of time slot limitations.

VISITORS

De Zhao Kong, a Ph.D. student from China, visited us from 20 of October 2017 to 26 of October 2018 in order to work on reviews related to Chinese medical herbs as well as methodology of Chinese clinical trials that have assessed the benefits and harms of medical herbs. During this time, De Zhao managed to publish two review protocols as a first author with the following titles: *Acupuncture for chronic hepatitis B* and *Xiao Chai Hu Tang, a Chinese herbal medicine formula, for chronic hepatitis B*.

Ning Liang, also a Ph.D. student from China, who came together with *De Zhao Kong*, is still with us, working on two other reviews as a first author, the protocols of which have also been published: *Radix Sophorae flavescens for chronic hepatitis B* and *Radix Sophorae flavescens versus antiviral drugs for chronic hepatitis B*. Ning Liang's work is also related to the methodology of Chinese trials that have assessed medicinal herbs.

Both students received governmental and university funding from China.

Beatriz Sanchez-Jimenez, from Mexico, paid us a visit from 1 of August to 26 October 2018. Beatriz worked on two review protocols, ensuing from a previously developed systematic review ‘*Antibiotic prophylaxis for cirrhotic patients with upper gastrointestinal bleeding*’, being considered as outdated in terms of last date of search for trials.

The *Antibiotic prophylaxis versus placebo or no intervention for people with cirrhosis and variceal bleeding* protocol is now published, and the *Antibiotic prophylaxis for people with cirrhosis and variceal bleeding* protocol is currently with a copy-editor. The plan is that the reviews, when finalized, will replace the current single review *Antibiotic prophylaxis for cirrhotic patients with upper gastrointestinal bleeding*.

Kurinchi Selvan Gurusamy, from UK, a CHBG editor and Deputy Co-ordinating editor, is paying us a visit between 5 to 7 of November. Kurinchi has been working on methodological issues related to Trial Sequential Analysis.

Filipa Markotic and *Svjetlana Grgic*, both from Bosnia and Herzegovina, arrived at the CHBG Editorial Team office on 6 of November 2018 and will leave on 28 of November. The aim of their visit is to learn about Cochrane methodology of systematic review and preparation, and they have already started working on a review entitled '*Antibiotics for people with cholangitis or cholecystitis or both*'. This review title will replace an outdated protocol published in 2002 with the title '*Antibiotics for cholangitis and/or cholecystitis*'.

Their visit is sponsored by their own institutions 'University Hospital Center Mostar' and 'University of Mostar, School of Medicine'.

We thank heartily all our visitors for their visits and arduous work.

THE COCHRANE SCIENTIFIC COMMITTEE

Cochrane Scientific Committee will on 8 of November discuss the use of sequential analysis methods in Cochrane systematic reviews, including the use of Trial Sequential Analysis.

STAY UPDATED

We kindly urge you to stay updated about recent changes and updates related to Cochrane and review preparation through the cochrane.org website.

Among the structural changes is the creation of eight Networks of Cochrane Review Groups (CRGs) www.cochrane.org/about-us/our-global-community.

The CHBG falls within the 'Cochrane Long-Term Conditions and Ageing 1' network. The other groups within our Network are Cochrane Inflammatory Bowel Disease; Cochrane Kidney and Transplant; Cochrane Metabolic and Endocrine Disorders, and Cochrane Upper GI and Pancreatic Diseases groups.

Parts of the MECIR Standards

<https://community.cochrane.org/mecir-manual> and parts of the Handbook

<https://training.cochrane.org/handbook>

have also been updated. You may find information on webinars at <https://training.cochrane.org/cli-webinars>) or series of online learning modules

<https://www.cochrane.org/news/cochrane-interactive-learning>) etc.

The Cochrane Hepato-Biliary Group (The CHBG) Newsletter is written, edited, and published in electronic and paper format by Dimitrinka Nikolova and Christian Gluud at The CHBG Editorial Office in Copenhagen, Denmark.

It is issued twice a year and it is also distributed for free world-wide to all people on The CHBG member list who have contributed, are contributing, or have shown interest in the work of The CHBG or in this CHBG Newsletter.

The purpose with The CHBG Newsletter is to inform readers about activities of The CHBG.

Editorial CHBG staff at The CHBG Editorial Office:

Christian Gluud, Co-ordinating & Criticism Editor, E-mail: cgluud@ctu.dk;
Dimitrinka Nikolova, Managing Editor, E-mail: dimitrinka.nikolova@ctu.dk;
Sarah Louise Klingenberg, Information Specialist, E-mail: slk@ctu.dk

Postal address

The Cochrane Hepato-Biliary Group/The Copenhagen Trial Unit,
Centre for Clinical Intervention Research
Department 7812, Rigshospitalet, Blegdamsvej 9, Copenhagen Ø, DK-2100
Tel. +45 3545 7169 or +45 3545 7175 Fax +45 3545 7101
Web site: hbg.cochrane.org

Visiting address

Department 7812, Tagensvej 22, 2nd floor, Copenhagen N, DK-2200